Resveratrol for the Prevention of Bone Loss in Postmenopausal Women


Report Abuse


The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.

Targeted Conditions

Study Overview

Start Date
January 2, 2024
Completion Date
December 31, 2024
Date Posted
February 9, 2024
Accepts Healthy Volunteers?


Full Address
University of Delaware
Newark, Delaware 19716, United States


Eligibility Criteria
Inclusion Criteria:

1 to 5 years postmenopausal women with low bone mass

Exclusion Criteria:

Taking blood thinners, endocrine, or neuroactive drugs
Hormone therapy
Diagnosed: Metabolic bone disease, renal disease, kidney stones, cancer, cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease
Severe menopausal symptoms, serious mood alterations, sleep disturbances
Abnormal uterine bleeding, endometriosis, pelvic inflammatory disease
Endometrial polyps, and significant uterine fibroids
Smokers (≥ 20 cigarettes per day)
BMI <20 and > 30 kg/m2
Intolerance or allergic reaction to resveratrol, microcrystalline cellulose, grapes, red wine, or blueberries

Study Contact Info

Study Contact Name
Sheau Ching Chai, PhD, RD
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

Resveratrol for the Prevention of Bone Loss in Postmenopausal Women 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
FDA Regulated Device?
Detailed Description
34 women will be randomly assigned to two groups: 1) the placebo group and 2) the resveratrol group. The resveratrol group will receive 500 mg resveratrol daily for 24 weeks, and placebo group will receive placebo pills. Both groups will receive 500 mg calcium plus 400 IU vitamin D daily.

Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention. Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks.
NCTid (if applicable)